Florida Eye Associates | Melbourne, FL

Research site

(Unclaimed)

Location

502 East New Haven Avenue, Melbourne, Florida, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

KSI-301

Lampalizumab

Aflibercept

RO7200220

KHK4951

Faricimab

Zimura

AGN-190584

BI 771716

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 42 total trials

4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Enrolling

Neovascular (Wet) Age-Related Macular Degeneration

Biological: 4D-150 IVT

Biological: Aflibercept IVT

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) (GLOW2)

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

Active, not recruiting

Diabetic Retinopathy

Drug: Tarcocimab

Other: Sham injection

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) (Pregonda)

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-as...

Enrolling

Diabetic Macular Edema

Drug: RO7497372

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling

Neovascular Age-Related Macular Degeneration

Drug: PDS Implant with Ranibizumab 100 mg/mL